Weight & metabolic
Tirzepatide
Dual GIP/GLP-1 Agonist
A newer dual-action peptide that activates both GIP and GLP-1 receptors. Works on two appetite pathways simultaneously for enhanced metabolic effects.
Also known as: Mounjaro, Zepbound, tirz
- Status
- Tirzepatide is approved by the U.S. FDA and has official prescribing information.
- Evidence
- Approved labeling. Official prescribing information exists, based on clinical trials in people.
- Half-life
- ~5 days
- How it's taken
- Weekly subcutaneous injection
- Mechanism
- Incretin (GLP-1 / GIP / glucagon / amylin)
- Pathways
- GLP-1, GIP
How Tirzepatide works
Targets two incretin hormones at once — GLP-1 and GIP. This dual action enhances insulin release, suppresses glucagon, slows gastric emptying, and reduces appetite more effectively than single-target drugs.
What research has looked at
- Superior weight loss compared to single-target peptides
- Strong blood sugar control
- Improved insulin sensitivity
- Reduced cardiovascular risk markers
Evidence level: Approved labeling. Official prescribing information exists, based on clinical trials in people. These are areas studied or reported, not promised effects.
Reported side effects and risks
- Nausea and vomiting (common early on)
- Diarrhea or constipation
- Decreased appetite (beyond intended effect)
- Injection site reactions
- Rare: thyroid concerns in animal studies
Sources
- FDA approved-drug listing for tirzepatide · U.S. Food & Drug Administration
- DailyMed prescribing information for tirzepatide · NIH · DailyMed
- PubMed research on tirzepatide SURPASS SURMOUNT trial · NIH · National Library of Medicine
- DrugBank record for tirzepatide · DrugBank
Track Tirzepatide in Peptide Vault
Log every dose, set reminders on your own schedule, rotate injection sites and keep your vials organized. Peptide Vault records what you enter. It doesn't recommend compounds or doses. iPhone, on-device.
Related compounds
Tirzepatide FAQ
What is Tirzepatide?
A newer dual-action peptide that activates both GIP and GLP-1 receptors. Works on two appetite pathways simultaneously for enhanced metabolic effects.
How does Tirzepatide work?
Targets two incretin hormones at once — GLP-1 and GIP. This dual action enhances insulin release, suppresses glucagon, slows gastric emptying, and reduces appetite more effectively than single-target drugs.
Is Tirzepatide FDA approved?
Yes. Tirzepatide is approved by the U.S. FDA and has official prescribing information. Evidence level: approved labeling. Official prescribing information exists, based on clinical trials in people.
What is the half-life of Tirzepatide?
Reported half-life: ~5 days.
How is Tirzepatide taken?
Weekly subcutaneous injection.
What side effects have been reported with Tirzepatide?
Reported in the sources: Nausea and vomiting (common early on); Diarrhea or constipation; Decreased appetite (beyond intended effect); Injection site reactions; Rare: thyroid concerns in animal studies.
Educational summary compiled from the sources listed above. Not medical advice. Peptide Vault does not sell, source or recommend any compound. Talk to a qualified clinician before starting or changing anything.